Clinical Trial Update: Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 Japanese study evaluating the efficacy and safety of pomalidomide in relapsed and refractory multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Pomalyst (pomalidomide)

Snippet

Sponsor: Celgene Corporation | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2015-11-10